DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of PsoriasisGlobeNewsWire • 07/21/22
Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results AnnouncementPRNewsWire • 07/21/22
Eli Lilly to supply another 150,000 doses of COVID treatment to the governmentMarket Watch • 06/29/22
Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment optionsPRNewsWire • 06/29/22
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaPRNewsWire • 06/27/22
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell CarcinomaPRNewsWire • 06/21/22
Eli Lilly and Company (LLY) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/14/22
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia AreataPRNewsWire • 06/14/22